Detalles de la búsqueda
1.
Comparison of continuous measures across diagnostic PD-L1 assays in non-small cell lung cancer using automated image analysis.
Mod Pathol
; 33(3): 380-390, 2020 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-31527709
2.
Computational modelling prediction and clinical validation of impact of benralizumab on airway smooth muscle mass in asthma.
Eur Respir J
; 54(5)2019 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-31391226
3.
Formation, clearance, deposition, pathogenicity, and identification of biopharmaceutical-related immune complexes: review and case studies.
Toxicol Pathol
; 42(4): 725-64, 2014 Jun.
Artículo
en Inglés
| MEDLINE | ID: mdl-24705884
4.
ASCT2-Targeting Antibody-Drug Conjugate MEDI7247 in Adult Patients with Relapsed/Refractory Hematological Malignancies: A First-in-Human, Phase 1 Study.
Target Oncol
; 19(3): 321-332, 2024 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-38683495
5.
Opposing roles of membrane and soluble forms of the receptor for advanced glycation end products in primary respiratory syncytial virus infection.
J Infect Dis
; 205(8): 1311-20, 2012 Apr 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-22262795
6.
Gemcitabine and cisplatin plus durvalumab with or without tremelimumab in chemotherapy-naive patients with advanced biliary tract cancer: an open-label, single-centre, phase 2 study.
Lancet Gastroenterol Hepatol
; 7(6): 522-532, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35278356
7.
Optimal PD-L1-high cutoff for association with overall survival in patients with urothelial cancer treated with durvalumab monotherapy.
PLoS One
; 15(4): e0231936, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32339189
8.
The Society for Immunotherapy of Cancer statement on best practices for multiplex immunohistochemistry (IHC) and immunofluorescence (IF) staining and validation.
J Immunother Cancer
; 8(1)2020 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-32414858
9.
Safety and Efficacy of Durvalumab and Tremelimumab Alone or in Combination in Patients with Advanced Gastric and Gastroesophageal Junction Adenocarcinoma.
Clin Cancer Res
; 26(4): 846-854, 2020 02 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-31676670
10.
Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma.
Diagn Pathol
; 14(1): 99, 2019 Sep 02.
Artículo
en Inglés
| MEDLINE | ID: mdl-31477145
11.
Automated image analysis of NSCLC biopsies to predict response to anti-PD-L1 therapy.
J Immunother Cancer
; 7(1): 121, 2019 05 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-31060602
12.
Analytical Validation and Clinical Utility of an Immunohistochemical Programmed Death Ligand-1 Diagnostic Assay and Combined Tumor and Immune Cell Scoring Algorithm for Durvalumab in Urothelial Carcinoma.
Arch Pathol Lab Med
; 143(6): 722-731, 2019 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-30457897
13.
Safety and efficacy of durvalumab in patients with head and neck squamous cell carcinoma: results from a phase I/II expansion cohort.
Eur J Cancer
; 109: 154-161, 2019 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-30731276
14.
Clinical Activity, Tolerability, and Long-Term Follow-Up of Durvalumab in Patients With Advanced NSCLC.
J Thorac Oncol
; 14(10): 1794-1806, 2019 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-31228626
15.
Deep Semi Supervised Generative Learning for Automated Tumor Proportion Scoring on NSCLC Tissue Needle Biopsies.
Sci Rep
; 8(1): 17343, 2018 11 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-30478349
16.
Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay.
Diagn Pathol
; 13(1): 47, 2018 Jul 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-30041679
17.
Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study.
Lancet Respir Med
; 6(6): 451-460, 2018 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-29773326
18.
SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads.
Clin Cancer Res
; 24(24): 6570-6582, 2018 12 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-30131388
19.
Agreement between Programmed Cell Death Ligand-1 Diagnostic Assays across Multiple Protein Expression Cutoffs in Non-Small Cell Lung Cancer.
Clin Cancer Res
; 23(14): 3585-3591, 2017 Jul 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-28073845
20.
Development of a programmed cell death ligand-1 immunohistochemical assay validated for analysis of non-small cell lung cancer and head and neck squamous cell carcinoma.
Diagn Pathol
; 11(1): 95, 2016 Oct 08.
Artículo
en Inglés
| MEDLINE | ID: mdl-27717372